Table 1. Characteristics of AML-M6 vs AML-Other Patients (excluding APL).
| Characteristics | AML-M6 | AML-Other | P |
|---|---|---|---|
| No. Patients | 108 | 2,884 | |
| Male Sex, no. (%) | 70 (65) | 1,600 (55) | 0.05 |
| Median Age, years (range) | 60 (17-85) | 59 (14-89) | 0.009 |
| PS 3-4, no. (%) | 7 (6) | 259 (9) | 0.37 |
| Prior AHD/MDS, no. (%) | 54 (50) | 1,169 (1,169) | 0.05 |
| Prior Chemo or XRT, no. (%) | 27 (25) | 423 (15) | 0.003 |
| Median WBC, ×109/L (range) | 2.4 (0.34-45.1) | 9.7 (0.2-433) | < 0.001 |
| Median Hb, g/dL (range) | 7.7 (2.5-12.6) | 8.3 (2-16.1) | < 0.001 |
| Median Platelets, × 109/L (range) | 38 (3-222) | 49 (1-2,292) | < 0.001 |
| Median PB Blasts, % (range) | 3 (0-78) | 24 (0-99) | < 0.001 |
| Median BM Blasts, % (range) | 22 (2-92) | 53 (0-99) | < 0.001 |
| Median Beta 2 Microglobulin, mg/L (range) | 2.3 (1.2-13.3) | 2.8 (0-31.3) | 0.004 |
| Median LDH, IU/L (range) | 739 (226-25,980) | 916 (66-58,586) | 0.019 |
| Cytogenetics | < 0.001 | ||
| • Poor | 75 (69) | 1,329 (46) | |
| • Intermediate | 31 (29) | 1,129 (39) | |
| • Favorable | 0 (0) | 255 (9) | |
| • Complex | 56 (52) | 654 (23) | < 0.001 |
| BM Dysplasia* | 85 | 1830 | |
| • Granulocytic | 38 (45) | 605 (33) | 0.026 |
| • Erythroid | 66 (78) | 563 (31) | < 0.001 |
| • Megakaryocytic | 36 (42) | 353 (19) | < 0.001 |
| Protected Environment | 66 (61) | 1,713 (59) | 0.71 |
*
There were 85 evaluable patients in the AML-M6 group and 1,830 patients in the AML-Other group. BM – bone marrow; Chemo – chemotherapy; PB – peripheral blood; PS – performance status; XRT – radiotherapy